Login to Your Account



Celera Gets Bayer Compounds To Help Build Clinical Pipeline

By Brady Huggett


Wednesday, October 9, 2002
Knowing that even the most lofty tasks are accomplished one move at a time, Celera Genomics Group made a move pursuing its own lofty goal of becoming a biopharmaceutical company by acquiring a collection of early compounds from Bayer AG. (Bioworld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription